Shuta Tomida

Shuta Tomida

Auto-generated profile, based on publicly available information

Shuta Tomida

Center for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2020 in Journal of Molecular Medicine
Verified
Journal Article
Closed access
PDF file
KAKota Araki
Kota Araki
RKRie Kinoshita
Rie Kinoshita
NTNahoko Tomonobu
Nahoko Tomonobu
YGYuma Gohara
Yuma Gohara
STShuta Tomida
Shuta Tomida
Masakiyo SakaguchiMasakiyo Sakaguchi
Masakiyo Sakaguchi

1 April 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
HHHidetoshi Hayashi
Hidetoshi Hayashi
KCKenji Chamoto
Kenji Chamoto
RHRyusuke Hatae
Ryusuke Hatae
TKTakashi Kurosaki
Takashi Kurosaki
YTYosuke Togashi
Yosuke Togashi
THTasuku Honjo
Tasuku Honjo
BACKGROUND: Precise stratification of patients with non–small cell lung cancer (NSCLC) is needed for appropriate application of PD-1/PD-L1 blockade therapy. METHODS: We measured soluble forms of the immune-checkpoint molecules PD-L1, PD-1, and CTLA-4 in plasma of patients with advanced NSCLC before PD-1/PD-L1 blockade. A prospective biomarker-finding trial (cohort A) included 50 previously treated patients who received nivolumab. A retrospective observational study was performed for patients treated with any PD-1/PD-L1 blockade therapy (cohorts B and C), cytotoxic chemotherapy (cohort D), or targeted therapy (cohort E). Plasma samples from all patients were assayed for soluble immune-checkpoint molecules with a highly sensitive chemiluminescence-based assay. RESULTS: Nonresponsiveness to PD-1/PD-L1 blockade therapy was associated with higher concentrations of these soluble immune factors among patients with immune-reactive (hot) tumors. Such an association was not apparent for patients treated with cytotoxic chemotherapy or targeted therapy. Integrative analysis of tumor size, PD-L1 expression in tumor tissue (tPD-L1), and gene expression in tumor tissue and peripheral CD8 + T cells revealed that high concentrations of the 3 soluble immune factors were associated with hyper or terminal exhaustion of antitumor immunity. The combination of soluble PD-L1 (sPD-L1) and sCTLA-4 efficiently discriminated responsiveness to PD-1/PD-L1 blockade among patients with immune-reactive tumors. CONCLUSION: Combinations of soluble immune factors might be able to identify patients unlikely to respond to PD-1/PD-L1 blockade as a result of terminal exhaustion of antitumor immunity. Our data suggest that such a combination better predicts, along with tPD-L1, for the response of patients with NSCLC. TRIAL REGISTRATION: UMIN000019674. FUNDING: This study was funded by Ono Pharmaceutical Co. Ltd. and Sysmex Corporation.

13 September 2019 in Journal for ImmunoTherapy of Cancer
Verified
Journal Article
Open access
PDF file
KHKoji Haratani
Koji Haratani
HHHidetoshi Hayashi
Hidetoshi Hayashi
TTTakayuki Takahama
Takayuki Takahama
YNYasushi Nakamura
Yasushi Nakamura
STShuta Tomida
Shuta Tomida
KNKazuhiko Nakagawa
Kazuhiko Nakagawa
Background Immune checkpoint inhibitors (ICIs) confer a survival benefit in many cancer types. Given that the survival outcome for cancer of unknown primary site (CUP) remains poor, we investigated the potential of CUP for immunotherapy. Methods A total of 164 patients with CUP (favorable subset, 34 patients; unfavorable subset, 130 patients) who were treated between January 2009 and March 2017 was identified from a review of medical records at Kindai University Hospital. They included 92 patients for whom pretreatment tumor tissue was available both for determination of programmed cell death–ligand 1 expression and tumor-infiltrating lymphocyte (TIL) density by immunohistochemistry (IHC) and for immune-related gene expression profiling (irGEP). The results of irGEP for CUP were compared with published data for ICI-treated solid cancers classified into progressive disease (PD) and non-PD subsets according to their best response to ICIs. Results The median overall survival of all CUP patients was 29.3 months (95% confidence interval [CI], 15.7–not reached) and 7.1 months (95% CI, 5.0–9.4) for favorable and unfavorable subsets, respectively. IHC and irGEP revealed that pretreatment immune activity—including expression of immune checkpoint molecules—for CUP was similar to that for ICI-responsive malignancies (antitumor immune cell signatures: CUP versus PD, P = 0.002–0.067; CUP versus non-PD, P = 0.591–0.999), although VEGFA expression was associated with suppression of antitumor immunity in CUP (P = 0.008, false discovery rate = 0.010). In addition, one case of CUP in the unfavorable subset that was associated with prominent PD-L1 expression on TILs and showed a durable response to nivolumab is presented. Conclusions The survival outcome of CUP remains unsatisfactory. However, our clinical and immune profiling of CUP has revealed a potential to benefit from immunotherapy, with ICIs thus being a potential option for CUP treatment.

11 January 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
MOMay Wathone Oo
May Wathone Oo
HKHotaka Kawai
Hotaka Kawai
KTKiyofumi Takabatake
Kiyofumi Takabatake
STShuta Tomida
Shuta Tomida
Takanori EguchiTakanori Eguchi
Takanori Eguchi
HNHitoshi Nagatsuka
Hitoshi Nagatsuka
Accumulating evidence has shown that cancer stroma and BM-derived cells (BMDCs) in the tumor microenvironment (TME) play vital roles in tumor progression. However, the mechanism by which oral cancer stroma recruits any particular subset of BMDCs remains largely unknown. Here, we sought to identify the subset of BMDCs that is recruited by cancer stroma. We established a sequential transplantation model in BALB/c nude mice, including (a) BM transplantation of GFP-expressing cells and (b) coxenografting of patient-derived stroma (PDS; 2 cases, designated PDS1 and PDS2) with oral cancer cells (HSC-2). As controls, xenografting was performed with HSC-2 alone or in combination with normal human dermal fibroblasts (HDF). PDS1, PDS2, and HDF all promoted BMDC migration in vitro and recruitment in vivo. Multicolor immunofluorescence revealed that the PDS coxenografts recruited Arginase-1 + CD11b + GR1 + GFP + cells, which are myeloid-derived suppressor cells (MDSCs), to the TME, whereas the HDF coxenograft did not. Screening using microarrays revealed that PDS1 and PDS2 expressed CCL2 mRNA (encoding C-C motif chemokine ligand 2) at higher levels than did HDF. Indeed, PDS xenografts contained significantly higher proportions of CCL2 + stromal cells and CCR2 + Arginase-1 + CD11b + GR1 + MDSCs (as receiver cells) than the HDF coxenograft. Consistently, a CCL2 synthesis inhibitor and a CCR2 antagonist significantly inhibited the PDS-driven migration of BM cells in vitro. Furthermore, i.p. injection of the CCR2 antagonist to the PDS xenograft models significantly reduced the CCR2 + Arginase-1 + CD11b + GR1 + MDSC infiltration to the TME. In conclusion, oral cancer stroma–secreted CCL2 is a key signal for recruiting CCR2 + MDSCs from BM to the TME.

8 July 2022 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
KNKazuya Nishii
Kazuya Nishii
KOKadoaki Ohashi
Kadoaki Ohashi
STShuta Tomida
Shuta Tomida
TNTakamasa Nakasuka
Takamasa Nakasuka
AHAtsuko Hirabae
Atsuko Hirabae
KKKatsuyuki Kiura
Katsuyuki Kiura
Epidermal growth factor receptor (EGFR) is the most frequently mutated driver oncogene in nonsmoking-related, non–small cell lung cancer (NSCLC). EGFR-mutant NSCLC has a noninflamed tumor microenvironment (TME), with low infiltration by CD8+ T cells and, thus, immune-checkpoint inhibitors, such as antiprogrammed cell death-1 (anti–PD-1), have weak antitumor effects. Here, we showed that CD8+ T-cell responses were induced by an EGFR-tyrosine kinase inhibitor (TKI) in syngeneic Egfr-mutant NSCLC tumors, which was further pronounced by the sequential dual blockade of PD-1 and vascular endothelial growth factor receptor 2 (VEGFR2). However, the simultaneous triple blockade had no such effect. The PD-1/VEGFR2 dual blockade did not exert tumor-inhibitory effects without pretreatment with the EGFR-TKI, suggesting that the treatment schedule is crucial for the efficacy of the dual blockade therapy. Pretreatment with EGFR-TKI increased the CD8+ T-cell/regulatory T-cell (Treg) ratio, while also increasing the expression of immunosuppressive chemokines and chemokine receptors, as well as increasing the number of M2-like macrophages, in the TME. Discontinuing EGFR-TKI treatment reversed the transient increase of immunosuppressive factors in the TME. The subsequent PD-1/VEGFR2 inhibition maintained increased numbers of infiltrating CD8+ T cells and CD11c+ dendritic cells. Depletion of CD8+ T cells in vivo abolished tumor growth inhibition by EGFR-TKI alone and the sequential triple therapy, suggesting that EGFR inhibition is a prerequisite for the induction of CD8+ T-cell responses. Our findings could aid in developing an alternative immunotherapy strategy in patients with cancers that have driver mutations and a noninflamed TME.

21 June 2021 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
AMAkihiro Miura
Akihiro Miura
DYDaisuke Yamada
Daisuke Yamada
MNMasahiro Nakamura
Masahiro Nakamura
STShuta Tomida
Shuta Tomida
DSDai Shimizu
Dai Shimizu
Takeshi TakaradaTakeshi Takarada
Takeshi Takarada